Industry Policy Committee Study Group on Extending Healthy Life Expectancy and Driving Economic Growth ~Toward the Future of the Pharmaceutical Industry
Report
Data in Charts 5 and 6 of the report published on April 20, 2012 were incorrect. The data has now been corrected in the published version. We apologize for any inconvenience caused.
Summary
We are pleased to announce the establishment of the "Study Group on Extending Healthy Life Expectancy and Driving Economic Growth - Toward the Future of the Pharmaceutical Industry" (hereinafter referred to as the "Study Group").
There is a mountain of social issues related to "health" and "economy." In particular, in the medical field, there are various issues such as the medical care delivery system due to the declining population and future financial concerns in response to the increasing demand for medical care due to the aging of the population.
In this study group, we invite experts who are leading academic research on the state of healthcare as a whole to participate and discuss from an "objective" and "neutral" standpoint how the pharmaceutical industry can contribute to resolving these issues, and to widely disseminate information on what the pharmaceutical industry should aim for based on the evidence obtained through evaluation and analysis. We hope that you will discuss how the pharmaceutical industry can contribute to the resolution of these issues from an "objective" and "neutral" standpoint.
The Japan Pharmaceutical Manufacturers Association (Chairman: Yasushi Okada, hereinafter referred to as "JAPMA") will do its utmost to support the discussions in the Study Group and will publicize the evidence and other information provided by the Study Group through its website.
For inquiries, please contact
Secretariat of the Pharmaceutical Manufacturers Association of Japan